Top Markets
#1 Wiki Cat Wiki Cat +42.56%
#2 Siren Siren +36.06%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.29%
#4 Ribbita by Virtuals Ribbita by Virtuals +19.07%
#5 PulseChain PulseChain +17.52%
#6 Velvet Velvet +17.46%
#7 KUB Coin KUB Coin +17.22%
#8 aPriori aPriori +16.23%
#9 Cysic Cysic +15.45%
#10 OpenEden OpenEden +15.08%
Coin of the day
Wiki Cat Wiki Cat
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD
Classement en actions #30914
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Prix de l'action
$0.343985
Capitalisation boursière
$15.40M
Changement (1 jour)
3.94%
Changement (1 an)
-25.19%
Pays
BE
Échange Celyad Oncology S.A. (CYAD)

Catégorie

Healthcare
Ratio P/B pour Celyad Oncology S.A. (CYAD)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Celyad Oncology S.A., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Celyad Oncology S.A. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE